Skip to main content

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Publication ,  Journal Article
Jafar, TH; Schmid, CH; Landa, M; Giatras, I; Toto, R; Remuzzi, G; Maschio, G; Brenner, BM; Kamper, A; Zucchelli, P; Becker, G; Himmelmann, A ...
Published in: Annals of internal medicine
July 2001

To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease.11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease.Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997.Data on 1860 nondiabetic patients were analyzed.Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% CI, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [CI, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [CI, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (CI, 0.51 to 0.94) for end-stage renal disease and 0.70 (CI, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d.Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annals of internal medicine

DOI

EISSN

1539-3704

ISSN

0003-4819

Publication Date

July 2001

Volume

135

Issue

2

Start / End Page

73 / 87

Related Subject Headings

  • Treatment Outcome
  • Sensitivity and Specificity
  • Randomized Controlled Trials as Topic
  • Proteinuria
  • Proportional Hazards Models
  • Logistic Models
  • Kidney Failure, Chronic
  • Kidney Diseases
  • Hypertension
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., … Levey, A. S. (2001). Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine, 135(2), 73–87. https://doi.org/10.7326/0003-4819-135-2-200107170-00007
Jafar, T. H., C. H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, et al. “Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.Annals of Internal Medicine 135, no. 2 (July 2001): 73–87. https://doi.org/10.7326/0003-4819-135-2-200107170-00007.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of internal medicine. 2001 Jul;135(2):73–87.
Jafar, T. H., et al. “Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.Annals of Internal Medicine, vol. 135, no. 2, July 2001, pp. 73–87. Epmc, doi:10.7326/0003-4819-135-2-200107170-00007.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of internal medicine. 2001 Jul;135(2):73–87.

Published In

Annals of internal medicine

DOI

EISSN

1539-3704

ISSN

0003-4819

Publication Date

July 2001

Volume

135

Issue

2

Start / End Page

73 / 87

Related Subject Headings

  • Treatment Outcome
  • Sensitivity and Specificity
  • Randomized Controlled Trials as Topic
  • Proteinuria
  • Proportional Hazards Models
  • Logistic Models
  • Kidney Failure, Chronic
  • Kidney Diseases
  • Hypertension
  • Humans